Age-related macular degeneration (AMD) is a progressive eye disease that affects the macula, a part of the retina responsible for central vision. The cells in the macula become damaged and begin to die, causing vision loss as a person ages. The disease is typically categorized into two types: dry age-related macular degeneration (AMD) and wet age-related macular degeneration (AMD). Dry AMD is more common and involves the formation of small, yellow deposits in the macula, while wet AMD is less common and involves the growth of abnormal blood vessels beneath the macula. In dry AMD, treatment options include vitamin supplements and lifestyle changes to reduce risk factors. In wet AMD, treatment involves medications that are injected into the eye to stop the growth of abnormal blood vessels. This treatment is called abnormal endothelial growth factor (anti-VEGF) therapy, and it works by blocking the protein that stimulates the growth of abnormal blood vessels.
According to our (Global Info Research) latest study, the global Age-Related Macular Degeneration (AMD) Treatment Drugs market size was valued at US$ 10400 million in 2023 and is forecast to a readjusted size of USD 15260 million by 2030 with a CAGR of 5.6% during review period.
The age-related macular degeneration (AMD) market trends are shaping the growth of the market. For instance rise in the adoption of age-related macular degeneration drugs (AMD) among the geriatric population suffering from age-related macular degeneration (AMD) drives the growth of the age-related macular degeneration (AMD) market size. For instance, according to the 2022 factsheet of World Health Organization, by 2030, 1 in 6 people in the world is projected to be aged 60 years or over, indicating a potential increase in the age-related macular degeneration (AMD) market size.
This report is a detailed and comprehensive analysis for global Age-Related Macular Degeneration (AMD) Treatment Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global Age-Related Macular Degeneration (AMD) Treatment Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2019-2030
Global Age-Related Macular Degeneration (AMD) Treatment Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2019-2030
Global Age-Related Macular Degeneration (AMD) Treatment Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2019-2030
Global Age-Related Macular Degeneration (AMD) Treatment Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Age-Related Macular Degeneration (AMD) Treatment Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Age-Related Macular Degeneration (AMD) Treatment Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Ionis Pharmaceuticals, Inc, Bausch Health Companies Inc, Regeneron Pharmaceuticals Inc, Biogen, Novartis AG, Sanofi S.A., Bayer AG, Coherus Biosciences Inc, F. Hoffmann-La Roche Ltd, Apellis Pharmaceuticals Inc, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Age-Related Macular Degeneration (AMD) Treatment Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Aflibercept
Ranibizumab
Others
Market segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Major players covered
Ionis Pharmaceuticals, Inc
Bausch Health Companies Inc
Regeneron Pharmaceuticals Inc
Biogen
Novartis AG
Sanofi S.A.
Bayer AG
Coherus Biosciences Inc
F. Hoffmann-La Roche Ltd
Apellis Pharmaceuticals Inc
AbbVie
Pfizer Inc.
Amgen Inc.
Samsung Bioepis
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Age-Related Macular Degeneration (AMD) Treatment Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Age-Related Macular Degeneration (AMD) Treatment Drugs, with price, sales quantity, revenue, and global market share of Age-Related Macular Degeneration (AMD) Treatment Drugs from 2019 to 2024.
Chapter 3, the Age-Related Macular Degeneration (AMD) Treatment Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Age-Related Macular Degeneration (AMD) Treatment Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Age-Related Macular Degeneration (AMD) Treatment Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Age-Related Macular Degeneration (AMD) Treatment Drugs.
Chapter 14 and 15, to describe Age-Related Macular Degeneration (AMD) Treatment Drugs sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Age-Related Macular Degeneration (AMD) Treatment Drugs. Industry analysis & Market Report on Age-Related Macular Degeneration (AMD) Treatment Drugs is a syndicated market report, published as Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030. It is complete Research Study and Industry Analysis of Age-Related Macular Degeneration (AMD) Treatment Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.